mTOR and cancer therapy

J. B. Easton, P. J. Houghton

Research output: Contribution to journalReview articlepeer-review

396 Scopus citations

Abstract

Proteins regulating the mammalian target of rapamycin (mTOR), as well as some of the targets of the mTOR kinase, are overexpressed or mutated in cancer. Rapamycin, the naturally occurring inhibitor of mTOR, along with a number of recently developed rapamycin analogs (rapalogs) consisting of synthetically derived compounds containing minor chemical modifications to the parent structure, inhibit the growth of cell lines derived from multiple tumor types in vitro, and tumor models in vivo. Results from clinical trials indicate that the rapalogs may be useful for the treatment of subsets of certain types of cancer. The sporadic responses from the initial clinical trials, based on the hypothesis of general translation inhibition of cancer cells are now beginning to be understood owing to a more complete understanding of the dynamics of mTOR regulation and the function of mTOR in the tumor microenvironment. This review will summarize the preclinical and clinical data and recent discoveries of the function of mTOR in cancer and growth regulation.

Original languageEnglish (US)
Pages (from-to)6436-6446
Number of pages11
JournalOncogene
Volume25
Issue number48
DOIs
StatePublished - Oct 16 2006
Externally publishedYes

Keywords

  • Autophagy
  • Cancer therapy
  • Hypoxia
  • Rapamycin
  • Stem cells
  • mTOR

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Fingerprint Dive into the research topics of 'mTOR and cancer therapy'. Together they form a unique fingerprint.

Cite this